News/ News/ Oncology Halozyme abandons cancer R&D as lead drug failed Phil Taylor Enhanze, Halozyme, Oncology, pancreatic cancer 0 Comment US biotech Halozyme has been forced to cut more than half its workforce and exit cancer R&D after Share X Halozyme abandons cancer R&D as lead drug failed https://pharmaphorum.com/news/halozyme-abandons-cancer-rd-as-lead-drug-failed/
